论文部分内容阅读
目的:探讨紫杉醇联合卡铂同步放疗在不宜外科治疗局部晚期非小细胞肺癌患者临床应用效果。方法:研究对象选取慈溪市人民医院2012年5月-2014年5月收治不宜外科治疗局部晚期非小细胞肺癌患者共180例,以随机数字表法分为A组(90例)和B组(90例),分别在卡铂+同步放疗基础上加用依托泊苷与紫杉醇辅助治疗;比较两组患者近期疗效,中位生存时间,治疗前后生活质量评分及III-IV级不良反应发生率等。结果:两组患者近期疗效比较差异无显著性意义(P>0.05);两组患者中位无进展时间和OS比较差异无显著性意义(P>0.05);B组患者治疗后EORTC QLQ-C30和KPS评分均显著高于A组(P<0.05);B组患者III-IV级骨髓抑制、消化道反应及疲倦发生率均显著低于A组(P<0.05);两组患者III-IV级放射性食管炎和放射性肺炎发生率比较差异无显著性(P>0.05)。结论:紫杉醇联合卡铂同步放疗用于不宜外科治疗局部晚期非小细胞肺癌治疗与常规化疗方案接近,但在提高生存质量和降低严重不良反应发生几率方面具有优势。
Objective: To investigate the clinical effect of paclitaxel combined with carboplatin in concurrent surgical treatment of locally advanced non-small cell lung cancer. Methods: A total of 180 patients with locally advanced non-small cell lung cancer who were unsuitable for surgical treatment were selected from Cixi People’s Hospital from May 2012 to May 2014. The patients were randomly divided into A group (n = 90) and B group 90 cases) were treated with etoposide and paclitaxel on the basis of carboplatin + concurrent radiotherapy. The short-term curative effect, median survival time, quality of life before and after treatment and the incidence of grade III-IV adverse reactions were compared between the two groups . Results: There was no significant difference in short-term curative effect between the two groups (P> 0.05). There was no significant difference in median progression-free time and OS between the two groups (P> 0.05). After treatment, the EORTC QLQ-C30 And KPS were significantly higher than those in group A (P <0.05). The level of III-IV myelosuppression, gastrointestinal reaction and fatigue in group B were significantly lower than those in group A (P <0.05) Grade esophagitis and radiation pneumonitis incidence was no significant difference (P> 0.05). Conclusions: Paclitaxel combined with carboplatin is not suitable for surgical treatment of locally advanced non-small cell lung cancer with conventional chemotherapy, but it has advantages in improving quality of life and reducing the incidence of serious adverse reactions.